Role of Ivabradine in. patients with stable coronary artery disease has been well established, however it has not been proved in AMI patients after PPCI yet. This study was designed to evaluate efficacy and adverse drug reactions of Ivabradine in collaboration with standard treatment of post PPCI patients with AMI. The results showed that Ivabradine as an add-on therapy to post PPCI patients with AMI standard treatment decreased heart rate, improved symptoms such as angina and dyspnea after 1 month of treatment (p 0.01), reduced major cardiovascular events, rehospitalisation for heart failure after 12 weeks of treatment compared to control group. Ivabradine was proved to be well-tolerated and safe in clinical treatment. In conclusion, Ivabraidine in collaboration with standard treatment improves the quality of life and the prognosis in AMI patients after PPCI.
- Đăng nhập để gửi ý kiến